Physician profile
Scott T Demarest
NPI 1255575767
$15,139.40
in general payments reported to CMS, 2019-2025
8 companies · $5,690 in 2025
The $5,690 reported for 2025 was more than what 88% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $2,833 · 2021: $5,200 · 2023: $960 · 2024: $32.33 · 2025: $5,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,100 · Consulting Fee: $960 · Food and Beverage: $379 · Travel and Lodging: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,100.00 |
| Consulting Fee | $960.00 |
| Food and Beverage | $378.99 |
| Travel and Lodging | $243.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $8,489.35 | 2019-2024 | Palynziq |
| H. Lundbeck A S | $5,100.00 | 2025 | |
| Immedica Pharma US, INC. | $960.00 | 2023 | |
| Ucb Sa | $360.39 | 2025 | Fintepla |
| Lundbeck LLC | $152.50 | 2025 | |
| Jazz Pharmaceuticals INC. | $77.16 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Demarest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.